SOUTH SAN FRANCISCO — Ambys Medicines, a company pioneering cell-based therapies for severe liver diseases, has completed a $47 million extension of its Series A financing. This brings the total Series A funding raised by Ambys to $107 million. Ambys is developing an entirely new approach to treating severe liver disease. The company’s liver-cell production […]
